Hypertensive heart disease: Benefit of carvedilol in hemodynamic, left ventricular remodeling, and survival
Open Access
- 8 January 2019
- journal article
- research article
- Published by SAGE Publications in Sage Open Medicine
- Vol. 7
Abstract
Objectives: The aim of this study was to determine if carvedilol improved structural and functional changes in the left ventricle and reduced mortality in patients with hypertensive heart disease. Methods: Blood pressure, heart rate, echocardiographic parameters, and laboratory variables, were assessed pre and post treatment with carvedilol in 98 eligible patients. Results: Carvedilol at a median dose of 50 mg/day during the treatment period in hypertensive heart disease lowered blood pressure 10/10 mmHg, heart rate 10 beats/min, improved left ventricular ejection fraction from baseline to follow-up (median: 6 years) (36%–47%)) and reduced left ventricular end-diastolic and end-systolic dimensions (62 vs 56 mm; 53 vs 42 mm, respectively, all p-values <0.01). Left ventricular ejection fraction increased in 69% of patients. Patients who did not have improved left ventricular ejection fraction had nearly six-fold higher mortality than those that improved (relative risk; 5.7, 95% confidence interval: 1.3–25, p = 0.022). Conclusion: Carvedilol reduced cardiac dimensions and improved left ventricular ejection fraction and cardiac remodeling in patients with hypertensive heart disease. These treatment-related changes had a favorable effect on survival.Keywords
This publication has 34 references indexed in Scilit:
- Pathological Ventricular RemodelingCirculation, 2013
- Use of carvedilol in hypertension: an updateVascular Health and Risk Management, 2012
- Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic EnigmaCurrent Cardiovascular Risk Reports, 2011
- The long-term outcome of patients with hypertensive cardiomyopathyJournal of Human Hypertension, 2005
- Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial InfarctionCirculation, 2004
- β-Blockers in Chronic Heart FailureCirculation, 2003
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyNew England Journal of Medicine, 2000
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Left Ventricular Hypertrophy and Mortality – Results from the Framingham StudyCardiology, 1992
- Echocardiographic findings of left ventricular hypertrophy and normalization of parameters of left ventricular function in patients with previous evidence of dilated and poorly contracting left ventricle and coexisting systemic hypertensionClinical Cardiology, 1989